A Yale-led research team developed a new RNA therapy, delivered through the nose, to treat mice infected with West Nile Virus. The innovative approach reduced the virus in the brain, allowing the immune system to destroy the virus and develop long-term protection against West Nile Virus disease, the researchers said.
The findings, published in Cell Host & Microbe, may represent a breakthrough strategy for treating West Nile Virus after virus invasion of the brain and the central nervous system, noted senior author Priti Kumar, M.D., associate professor of infectious disease at Yale School of Medicine.
There are no approved vaccines or effective therapies for West Nile Virus disease, a mosquito-borne condition. While many infected individuals have no symptoms, others — particularly the very young and older adults — can develop severe neurological problems and even die from the disease. The sporadic nature of the disease makes it exceedingly difficult for testing and implementing vaccines, said Kumar.
To investigate a possible new therapy to treat West Nile Virus disease, Kumar and her colleagues focused on a small “interfering” RNA molecule developed in her lab. The RNA acts against multiple mosquito-borne flaviviruses. To direct the RNA to infected cells, they packaged it in a peptide derived from the rabies virus, which is able to enter nerve cells. The final step was to the deliver the therapy through the nose where it could bypass natural barriers protecting the brain.
With this novel approach, the researchers found that the therapy reduced the virus in the brain, preventing harm to nerve cells. The treated mice had a 90% survival rate a few days after infection compared to mice treated with placebo. Significantly, noted the researchers, in the surviving mice, the immune system cleared the virus throughout the body, and also enabled long-term protection against future exposure.
The researchers concluded that the treatment offers both a promising late-stage therapy and lifelong immunity. It “prevents pathology in the brain and gives the mice a chance to develop a robust immune response,” said Kumar.
While the anatomy of the murine nose differs from that of humans, the researchers plan to study the therapy further with the hope it will be broadly applicable. “In translation, it should be an effective strategy for people,” she said.
If that is the case, the intranasal RNA therapy could theoretically be developed for treatment of other mosquito-borne diseases, such as St. Louis encephalitis, Japanese encephalitis, and perhaps Zika, the researchers noted.
The Latest on: RNA therapy
via Google News
The Latest on: RNA therapy
- PYC Therapeutics Highlights Continued Progress of Ocular and CNS Pipeline Programs and U.S. Expansion in First Quarter Updateon April 30, 2021 at 4:18 am
PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced a first quarter ...
- System4 Technologies: Universal therapy device for COVID-19, COVID-19 mutations, and other virus variants unveiledon April 30, 2021 at 4:10 am
Initial off-label-use applications with a special plasma design are promising. Possible use in intensive care medicine and treatment of long COVID. Planned large-scale study on universal use against ...
- A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemiaon April 30, 2021 at 3:21 am
Several genomic features have been found for acute myeloid leukaemia (AML) but targeted clinical genetic testing fails to predict prognosis. Here, the authors generate an AML prognostic score from RNA ...
- ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV Reservoirson April 29, 2021 at 6:00 am
ImmunityBio, Inc., a clinical-stage immunotherapy company, today announced that the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research has launched a Phase 2 clinical ...
- Texas A&M AgriLife receives grant to support research on bacteriophage therapyon April 28, 2021 at 10:46 pm
The National Institute of Allergy and Infectious Diseases, NIAID, part of the National Institutes of Health, NIH, has awarded $2.5 million in grants to support research on bacteriophage therapy, and ...
- Interrupting RNA activity can improve survival chances in pancreatic cancer patientson April 24, 2021 at 5:14 pm
During a recent study, researchers uncovered a molecular pathway that enhances chemotherapy resistance in some pancreatic cancer patients. A patient's response to therapy and their overall survival ...
- Interrupting RNA activity can improve cancer survivalon April 24, 2021 at 5:28 am
During a recent study researchers uncovered a molecular pathway that enhances chemotherapy resistance in some pancreatic cancer patients A patient response ...
- Interfering RNA nanoparticles could be a potential COVID-19 therapyon April 21, 2021 at 10:12 am
Study shows lipid nanoparticle-based siRNA is potent in suppressing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of coronavirus disease 2019 (COVID-19) – in cells ...
- Messenger RNA Vaccines: Beckoning of a New Era in Cancer Immunotherapyon April 21, 2021 at 7:01 am
A review of mRNA vaccine technology by ONCOLOGY® editorial board member Mehmet Sitki Copur, MD, FACP, explains the basis for progress in this field and reviews a number of new trials using this ...
via Bing News